PTC Therapeutics Inc. (PTCT) announced Friday morning that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended renewing the conditional marketing authorization of Translarna. The drug is a treatment for nonsense mutation Duchenne muscular dystrophy in ambulatory patients five years and older.
PTC Therapeutics gapped open sharply higher Friday, but traded in a range throughout the session. The stock closed up by 5.30 at $11.30, with volume at a 7-month high. PTC Therapeutics jumped to a 3-week high and re-crossed its 50 and 200-day moving averages.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.